Is combination ATG + PTCy prophylaxis always preferable to using each agent separately in haplo-HCT?

During the 49th Annual Meeting of the European Society for Blood and Marrow Transplantation (EBMT), the GvHD Hub was pleased to speak to Abdul-Hamid Bazarbachi, Jacobi Medical Centre, New York, US. We asked, Is combination anti-thymocyte globulin (ATG) + post-transplantation cyclophosphamide (PTCy) prophylaxis always preferable to using each agent separately in haploidentical hematopoietic cell transplant (haplo-HCT)?

Bazarbachi begins by outlining the indications and efficacy of both high-dose PTCy and ATG as sole therapies in GvHD prophylaxis. He goes on to discuss recent clinical research presented at the 49th Annual Meeting of the EBMT on the use of these treatments concurrently, with a focus on engraftment, relapse, and overall survival. Bazarbachi concludes by describing the implications of this data for the management of patients post haplo-HCT and the resulting incidence of GvHD.